Abstract
The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exerts a cancer cell-specific pro-apoptotic activity. This property made the TRAIL associated pathway one of the most promising strategies aimed at inducing tumor-selective death. In fact, several approaches have been considered to explore this pathway for cancer therapy, such as recombinant TRAIL, agonist antibodies for TRAIL receptors, and adenoviral TRAIL. However, all of these approaches have certain disadvantages that limit their clinical use. Our recent discovery that the complex PRAME/EZH2 is able to repress TRAIL expression, in a cancer-specific manner, suggests an alternative approach for combined cancer therapy. A genetic or pharmacological inhibition of TRAIL repressors in cancer cells could restore endogenous TRAIL expression, thereby overcoming some of the limitations of and/or cooperating with previous approaches.
Keywords: Apoptosis, cancer, EZH2, polycomb genes, PRAME, TRAIL, tumor necrosis factor, chromosome, natural killer cell, inflammation, autoimmune diseases, macrophages, metalloproteases, osteoprotegerin, conformational modification.
Current Molecular Medicine
Title:PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy
Volume: 13 Issue: 2
Author(s): D. D. De Carvalho, B. P. Mello, W. O. Pereira and G. P. Amarante-Mendes
Affiliation:
Keywords: Apoptosis, cancer, EZH2, polycomb genes, PRAME, TRAIL, tumor necrosis factor, chromosome, natural killer cell, inflammation, autoimmune diseases, macrophages, metalloproteases, osteoprotegerin, conformational modification.
Abstract: The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) exerts a cancer cell-specific pro-apoptotic activity. This property made the TRAIL associated pathway one of the most promising strategies aimed at inducing tumor-selective death. In fact, several approaches have been considered to explore this pathway for cancer therapy, such as recombinant TRAIL, agonist antibodies for TRAIL receptors, and adenoviral TRAIL. However, all of these approaches have certain disadvantages that limit their clinical use. Our recent discovery that the complex PRAME/EZH2 is able to repress TRAIL expression, in a cancer-specific manner, suggests an alternative approach for combined cancer therapy. A genetic or pharmacological inhibition of TRAIL repressors in cancer cells could restore endogenous TRAIL expression, thereby overcoming some of the limitations of and/or cooperating with previous approaches.
Export Options
About this article
Cite this article as:
De Carvalho D. D., Mello P. B., Pereira O. W. and Amarante-Mendes P. G., PRAME/EZH2-Mediated Regulation of TRAIL: A New Target for Cancer Therapy, Current Molecular Medicine 2013; 13 (2) . https://dx.doi.org/10.2174/1566524011313020006
DOI https://dx.doi.org/10.2174/1566524011313020006 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monoclonal Antibodies as a Tool for Structure-Function Studies of the MDR1-P-Glycoprotein
Current Protein & Peptide Science Clinically Relevant Extracellular-Matrix Scaffolds for Cell Transplantation and Vascular Repair
Current Vascular Pharmacology Cytotoxic and Apoptotic Effect of <i>Iris taochia</i> Plant Extracts on Human Breast Cancer (MCF-7) Cells
Current Proteomics Monoterpenes as Perspective to Chronic Pain Management: A Systematic Review
Current Drug Targets Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Cell Surface Nucleolin as a Target for Anti-Cancer Therapies
Recent Patents on Anti-Cancer Drug Discovery Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Biomacromolecule-Functionalized Nanoparticle-Based Conjugates for Potentiation of Anticancer Therapy
Current Cancer Drug Targets The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment
Current Cancer Therapy Reviews Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma
Current Cancer Drug Targets Adaptative and Developmental Responses to Stress in Aspergillus nidulans
Current Protein & Peptide Science Double-Edged Sword of Novel Anti-Cancer Treatment: Proteasome Inhibition in the Growth Plate Causes Impairment of Longitudinal Bone Growth
Current Pediatric Reviews Copper Compounds in Cancer Chemotherapy
Current Medicinal Chemistry The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Current Pharmaceutical Biotechnology Medicinal Plants and Cancer Chemoprevention
Current Drug Metabolism Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy Forms of Iron Binding in the Cells and the Chemical Features of Chelation Therapy
Mini-Reviews in Medicinal Chemistry Targeting mTOR Signaling Pathway in Ovarian Cancer
Current Medicinal Chemistry Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry